24
Participants
Start Date
September 10, 2015
Primary Completion Date
October 14, 2016
Study Completion Date
October 14, 2016
Concizumab
Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)
placebo
Administered subcutaneously (s.c., under the skin)
Novo Nordisk Investigational Site, Vienna
Novo Nordisk Investigational Site, Camperdown
Novo Nordisk Investigational Site, Melbourne
Novo Nordisk Investigational Site, New York
Novo Nordisk Investigational Site, Berlin
Novo Nordisk Investigational Site, Bangkok
Novo Nordisk Investigational Site, Baltimore
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Rennes
Novo Nordisk Investigational Site, Bornova-IZMIR
Novo Nordisk Investigational Site, Nantes
Novo Nordisk Investigational Site, Indianapolis
Novo Nordisk Investigational Site, Duisburg
Novo Nordisk Investigational Site, Dnipropetrovsk
Novo Nordisk Investigational Site, Kuala Lumpur
Novo Nordisk Investigational Site, Iowa City
Novo Nordisk Investigational Site, Tel Litwinsky
Novo Nordisk Investigational Site, Milwaukee
Novo Nordisk Investigational Site, Homburg
Novo Nordisk Investigational Site, Bron
Novo Nordisk Investigational Site, Houston
Novo Nordisk Investigational Site, Lviv
Novo Nordisk Investigational Site, Kuching
Novo Nordisk Investigational Site, Portland
Novo Nordisk Investigational Site, Torrance
Novo Nordisk Investigational Site, Zagreb
Novo Nordisk Investigational Site, Amsterdam
Novo Nordisk Investigational Site, Nijmegen
Novo Nordisk Investigational Site, Utrecht
Novo Nordisk Investigational Site, Warsaw
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, Sheffield
Novo Nordisk Investigational Site, Southampton
Lead Sponsor
Novo Nordisk A/S
INDUSTRY